AnPac Bio-Medical Science Co., Ltd.
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of AnPac Bio-Medical Science Co., Ltd. generated cash of -$55,060,000, which is more than the previous year. Cash used in financing activities reached the amount of $49,469,000 last year. Net change in cash is therefore -$7,381,000.
Cash Flow
| 2017 | -21.64M | -8.01M | 39.80M |
|---|---|---|---|
| 2018 | -31.14M | -2.68M | 36.27M |
| 2019 | -48.6M | -3.46M | 46.10M |
| 2020 | -58.96M | -2.48M | 60.92M |
| 2021 | -71.70M | -3.93M | 83.42M |
| 2022 | -55.06M | -1.59M | 49.46M |
ANPC Cash Flow Statement (2017 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 9.25M | 3.01M | 6.12M | 12.88M | 11.41M | 4.15M |
Operating activities | ||||||
Net income | -103.59M | -120.08M | -80.56M | -101.62M | -42.06M | -39.07M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 5.49M | 3.91M | 3.09M | 2.66M | 3.14M | 2.28M |
Stock-based compensation expense | 0 | 34.16M | 17.76M | 32.85M | 0 | 0 |
| Deferred income tax benefit | 0 | 34.16M | 17.76M | 32.85M | 0 | 0 |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | 2.89M | 1.53M | -7.25M | 1.28M | -1.09M | -1.25M |
Inventories | 285K | -180K | -44K | -555K | 178K | 421K |
Accounts payable | -626K | 360K | 350K | 182K | -843K | 740K |
Cash generated by operating activities | -55.06M | -71.70M | -58.96M | -48.6M | -31.14M | -21.64M |
Investing activities | ||||||
Purchases Of Investments | 0 | 0 | 0 | -21.22M | -13.55M | -7.05M |
Investments In Property Plant And Equipment | -1.59M | -3.97M | -2.49M | -3.16M | -2.84M | -2.62M |
Acquisitions Net | 0 | 41K | 0 | 371K | -3.54M | -3.34M |
Cash generated by investing activities | -1.59M | -3.93M | -2.48M | -3.46M | -2.68M | -8.01M |
Financing activities | ||||||
Common Stock Issued | 61.01M | 42.35M | 110.66M | 47.60M | 404K | 40.15M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -11.00M | 0 | -25.61M | 0 | -728K | 0 |
Repayments of term debt | 0 | -6M | -38.33M | 0 | -15.05M | 0 |
Cash used in financing activities | 49.46M | 83.42M | 60.92M | 46.10M | 36.27M | 39.80M |
Net Change In Cash | -7.38M | 6.23M | -3.10M | -6.76M | 1.47M | 7.25M |
Cash at end of period | 1.87M | 9.25M | 3.01M | 6.12M | 12.88M | 11.41M |
| Data source | Data source | Data source | Data source |